Código QR (código de barras bidimensional)

Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy

Background: Oral immunotherapy containing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals aged 4 to 17 years with peanut allergy than in pla...

ver descrição completa

Na minha lista:
Principais autores: J. Andrew Bird, MD, Caroline Nilsson, MD, Kari Brown, MD, Trinh Pham, MS, Stephen Tilles, MD, George du Toit, MB, BCh, Amal Assa’ad, MD
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2023-08-01
coleção:Journal of Allergy and Clinical Immunology: Global
Assuntos:
PTAH
oral immunotherapy
peanut allergy
peanut (Arachis hypogaea) allergen powder
pooled safety
immunologic outcomes
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2772829323000450
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados